PGI21 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Retreatment of Patients With Chronic Hepatitis C Virus Genotype I Infection
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.770
https://www.valueinhealthjournal.com/article/S1098-3015(12)02483-7/fulltext
Title :
PGI21 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Retreatment of Patients With Chronic Hepatitis C Virus Genotype I Infection
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02483-7&doi=10.1016/j.jval.2012.08.770
First page :
A329
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
279